TABLE 3.
Comparison of Clinical Parameters for Patients with In-Range Phosphorus during SO Follow-up
| Parameter | Baseline | SO follow-up | P-value |
|---|---|---|---|
| Patients with serum phosphorus ≤ 5.5 mg/dL for ≥ 3 months of SO follow-up (n=110) | |||
| Phosphate binder pills/day* | 9.3 (0.2) | 4.4 (0.2) | <0.0001 |
| Serum phosphorus (mg/dL) | 5.81 (0.08) | 4.97 (0.07) | <0.0001 |
| Albumin-corrected calcium (mg/dL) | 9.43 (0.06) | 9.36 (0.06) | 0.08 |
| Intact PTH (pg/mL) | 406 (33) | 425 (32) | 0.4 |
| Weight (kg) | 88.1 (2.3) | 87.5 (2.3) | 0.3 |
| Serum albumin (g/dL) | 3.70 (0.03) | 3.64 (0.03) | <0.001 |
| Phosphorus-attuned albumin (×103) | 0.68 (0.01) | 0.77 (0.01) | <0.0001 |
| Phosphorus-attuned nPCR (×103 dL/kg/day) | 0.18 (0.01) | 0.21 (0.01) | <0.001 |
| Serum creatinine (mg/dL) | 10.3 (0.4) | 10.2 (0.4) | 0.12 |
| Kru (mL/min/1.73 m2) | 3.58 (0.38) | 3.25 (0.34) | 0.3 |
| PD Kt/V | 1.57 (0.12) | 1.73 (0.09) | 0.3 |
| Total Kt/V | 2.2 (0.1) | 2.3 (0.1) | 0.3 |
| Subset of patients with serum phosphorus > 5.5 mg/dL at baseline (n=63) | |||
| Phosphate binder pills/day** | 9.9 (0.3) | 4.7 (0.3) | <0.0001 |
| Serum phosphorus (mg/dL) | 6.54 (0.10) | 5.10 (0.08) | <0.0001 |
| Albumin-corrected calcium (mg/dL) | 9.31 (0.09) | 9.36 (0.08) | 0.3 |
| Intact PTH (pg/mL) | 430 (32) | 391 (30) | 0.087 |
| Weight (kg) | 85.9 (2.7) | 87.1 (2.7) | 0.007 |
| Serum albumin (g/dL) | 3.71 (0.04) | 3.63 (0.04) | 0.001 |
| Phosphorus-attuned albumin (×103) | 0.59 (0.01) | 0.75 (0.01) | <0.0001 |
| Phosphorus-attuned nPCR (×103 dL/kg/day) | 0.17 (0.01) | 0.21 (0.01) | <0.0001 |
| Serum creatinine (mg/dL) | 11.7 (0.5) | 11.3 (0.5) | 0.002 |
| Kru (mL/min/1.73 m2) | 2.71 (0.44) | 2.40 (0.37) | 0.5 |
| PD Kt/V | 1.59 (0.17) | 1.80 (0.13) | 0.3 |
| Total Kt/V | 2.0 (0.2) | 2.2 (0.1) | 0.3 |
Values are expressed as least-squared means (standard error), p-values compare least-squared means between treatment periods
Abbreviations: Kru - residual urea clearance; nPCR - normalized protein catabolic rate; PD – peritoneal dialysis; PTH - parathyroid hormone; SO – sucroferric oxyhydroxide
Pill burden at baseline was calculated only for patients who received phosphate binder prescriptions through FreseniusRx (n=68). Follow-up PB pill burden for patients with no baseline binder available through FreseniusRx (n=42) was found to be 4.1 SO pills/day.
Pill burden at baseline was calculated only for patients who received phosphate binder prescriptions through FreseniusRx (n=29). Follow-up PB pill burden for patients with no baseline binder available through FreseniusRx (n=34) was found to be 4.4 SO pills/day.